Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: abridged summary of the Cochrane review

People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour. Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle...

Full description

Saved in:
Bibliographic Details
Main Authors: Hahne, Stefanie (Author) , Kunath, Frank (Author) , Coles, Bernadette (Author) , Dräger, Désirée Louisê (Author) , Krabbe, Laura-Maria (Author) , Dersch, Rick (Author) , Kilian, Samuel (Author) , Jensen, Katrin (Author) , Dahm, Philipp (Author) , Meerpohl, Jörg J. (Author)
Format: Article (Journal)
Language:English
Published: Jun 29, 2020
In: Investigative and clinical urology
Year: 2020, Volume: 61, Issue: 4, Pages: 349-354
ISSN:2466-054X
DOI:10.4111/icu.2020.61.4.349
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.4111/icu.2020.61.4.349
Get full text
Author Notes:Stefanie Schmidt, Frank Kunath, Bernadette Coles, Desiree Louise Draeger, Laura-Maria Krabbe, Rick Dersch, Samuel Kilian, Katrin Jensen, Philipp Dahm, Joerg J. Meerpohl
Description
Summary:People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour. Mitomycin C (MMC) and Bacillus Calmette-Guérin (BCG) are commonly used, competing forms of intravesical therapy for intermediate- or high-risk non-muscle invasive (Ta and T1) urothelial bladder cancer but their relative merits are somewhat uncertain. Although several systematic reviews and meta-analyses have been conducted on this topic, it still remains unclear what the optimal treatment dose and schedule might be, as well as the question of which people benefit most from one or the other agent.
Item Description:Gesehen am 29.10.2020
Physical Description:Online Resource
ISSN:2466-054X
DOI:10.4111/icu.2020.61.4.349